TY - JOUR
T1 - Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer
AU - Takai, Erina
AU - Nakamura, Hiromi
AU - Chiku, Suenori
AU - Kubo, Emi
AU - Ohmoto, Akihiro
AU - Totoki, Yasushi
AU - Shibata, Tatsuhiro
AU - Higuchi, Ryota
AU - Yamamoto, Masakazu
AU - Furuse, Junji
AU - Shimizu, Kyoko
AU - Takahashi, Hideaki
AU - Morizane, Chigusa
AU - Furukawa, Toru
AU - Yachida, Shinichi
N1 - Funding Information:
S.Y., C.M., and T.F. have received a grant from the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT), the Japan Agency for Medical Research and Development (AMED) (JP15cm0106138h0002). S.Y. and C.M. have received grants from the National Cancer Research and Development Fund (25-A-1 and 28-A-1). T.F. has received a grant from the Japan Society for the Promotion of Science, KAKENHI (#24390090). S.Y. has received a grant from the Takeda Science Foundation. For the remaining authors none were declared. The National Cancer Center Biobank is supported by the National Cancer Center Research and Development Fund, Japan.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Objective:The primary objective of this study was to identify novel genes that predispose people in the Japanese population to FPC.Summary of Background Data:Familial history of pancreatic cancer is an important risk factor but, to date, few genes predisposing individuals to increased risk of developing FPC have been identified.Methods:We performed whole-exome sequencing of germline DNA from 81 Japanese FPC patients. We also investigated somatic gene alterations in 21 matched tumor tissues through whole-exome sequencing and copy number analysis.Results:Our germline variants identified previously known FPC susceptibility genes such as ATM and BRCA2, and several novel tumor suppressor genes with potentially deleterious variants for FPC. Interestingly, somatic whole-exome analysis demonstrated that most tumor samples with suspicious loss of heterozygosity of candidate genes were KRAS wild-types, implying that these cases may not have required KRAS activation as a driver event for carcinogenesis.Conclusions:Our findings indicate that FPC patients harbor potentially deleterious causative germline variants in tumor suppressor genes, which are known to acquire somatic mutations in pancreatic cancer, and that somatic loss of heterozygosity of some FPC susceptibility genes may contribute to the development of FPC in the absence of somatic KRAS-activating mutation. Genetic testing for a wider variety of FPC-predisposition genes could provide better screening approach for high-risk groups of pancreatic cancer.
AB - Objective:The primary objective of this study was to identify novel genes that predispose people in the Japanese population to FPC.Summary of Background Data:Familial history of pancreatic cancer is an important risk factor but, to date, few genes predisposing individuals to increased risk of developing FPC have been identified.Methods:We performed whole-exome sequencing of germline DNA from 81 Japanese FPC patients. We also investigated somatic gene alterations in 21 matched tumor tissues through whole-exome sequencing and copy number analysis.Results:Our germline variants identified previously known FPC susceptibility genes such as ATM and BRCA2, and several novel tumor suppressor genes with potentially deleterious variants for FPC. Interestingly, somatic whole-exome analysis demonstrated that most tumor samples with suspicious loss of heterozygosity of candidate genes were KRAS wild-types, implying that these cases may not have required KRAS activation as a driver event for carcinogenesis.Conclusions:Our findings indicate that FPC patients harbor potentially deleterious causative germline variants in tumor suppressor genes, which are known to acquire somatic mutations in pancreatic cancer, and that somatic loss of heterozygosity of some FPC susceptibility genes may contribute to the development of FPC in the absence of somatic KRAS-activating mutation. Genetic testing for a wider variety of FPC-predisposition genes could provide better screening approach for high-risk groups of pancreatic cancer.
KW - familial pancreatic cancer
KW - susceptibility genes
KW - whole-exome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85126072538&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126072538&partnerID=8YFLogxK
U2 - 10.1097/SLA.0000000000004213
DO - 10.1097/SLA.0000000000004213
M3 - Article
C2 - 32826389
AN - SCOPUS:85126072538
SN - 0003-4932
VL - 275
SP - E652-E658
JO - Annals of Surgery
JF - Annals of Surgery
IS - 4
ER -